Journals / Bakırköy Tıp Dergisi / 2014 / Cilt: 10 - Sayı: 3

Determination of necessary parameters to decide the second treatment for those who failed a single dose methotrexate therapy

Tek Doz Metotreksat Tedavisi Başarısız Olanlarda İkinci Tedaviye Karar Vermede Önemli Olan Parametrelerin Belirlenmesi

Pages
107–110
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Conclusion: The most important parameter is hemodynamic instability to decide the second treatment for those failed a single dose methotrexate therapy

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Objective: To determine necessary parameters to decide the second treatment for those whofailed a single dose methotrexate therapy.
📊
Key Findings & Data:Material and methods: 32 ectopic pregnancy patients who fail a single dose methotrexate treatment between 2000 and 2010 have been divided into two groups for secondary treatment; surgical and medical treatments.
💡
Conclusion & Impact:Conclusion: The most important parameter is hemodynamic instability to decide the second treatment for those failed a single dose methotrexate therapy
🔬Design:Research Article
📍Scope:2000 Verileri
⚙️Variables:Domain Parameters

Abstract

Objective: To determine necessary parameters to decide the second treatment for those whofailed a single dose methotrexate therapy. Material and methods: 32 ectopic pregnancy patients who fail a single dose methotrexate treatment between 2000 and 2010 have been divided into two groups for secondary treatment; surgical and medical treatments. Clinical and laboratory characteristics of the patient groups were compared. Results: 23 patients were treated surgically and medical treatment was repeated in 9 patients. There was no difference in terms of gestational age, baseline serum ß-hCG level and the size of ectopic pregnancy for both surgical and medical treatment of the patients. Surgery was performed in all patients who developed hemodynamic instability. Serum ß-hCG values were significantly higher in patients with hemodynamic instability than those who are hemodynamically stable (10374±14.554 vs. 4225±3429, p:0.001). Conclusion: The most important parameter is hemodynamic instability to decide the second treatment for those failed a single dose methotrexate therapy

Özet

Amaç: Tek doz metotreksat tedavisi başarısız olanlarda ikinci tedaviye karar vermede önemli olan parametreleri belirlemek. Gereç ve Yöntem: 2000-2010 yılları arasında tek doz metotreksat tedavisi başarısız olan 32 ektopik gebelik hastası ikinci tedavi olarak cerrahi ya da medikal tedavi uygulamasına göre iki gruba ayrıldı. Hasta gruplarının klinik ve laboratuvar özellikleri karşılaştırıldı. Bulgular: 23 hastaya cerrahi uygulanırken 9 hastaya mükerrer medikal tedavi uygulandı. Cerrahi ve medikal tedavi yapılanlar arasında gebelik haftası, başlangıç serum ß-hCG düzeyi, ektopik gebelik boyutu açısından bir fark saptanmadı. Hemodinamik instabilite gelişen bütün hastalara cerrahi uygulandı. Hemodinamik instabilite gelişen hastalarda hemodinamisi stabil olanlara göre ß-hCG değerleri yüksek bulundu (10374±14.554 ve 4225±3429, p:0.001). Sonuç: Tek doz metotreksat tedavisi başarısız olanlarda ikinci tedaviye karar vermede hemodinamik instabilite en önemli parametre olarak gözükmektedir.

🔖

Cite This Article

KILIÇ, B. Ş., TÜTEN, A., ÖNCÜL, M., AÇIKGÖZ, A. S. (2014). Determination of necessary parameters to decide the second treatment for those who failed a single dose methotrexate therapy. Bakırköy Tıp Dergisi, Cilt: 10 - Sayı: 3, 107–110. https://ajindex.com/articles/132650

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (14)

  1. Berg CJ, Chang J, Callaghan WM, Whitehead SJ. Pregnancy-related mortality in the United States, 1991–1997. Obstet Gynecol 2003; 101: 289-296
  2. Wong JA, Clark JF. Correlation of symptoms with age and location of gestation in tubal pregnancy. J Natl Med Assoc 1968; 60: 221- 223
  3. Atasü T, Sahmay S (Eds). Jinekoloji, 2. Baski, Nobel Yayınevi, İstanbul 2001: s. 547-557
  4. Kirk E, Condous G, Bourne T. Ectopic pregnancy deaths: what should we be doing? Hosp Med 2004; 65: 657-660
  5. Stovall TG, Ling FW. Single dosemethotrexate: an expanded clinical trial. Am J Obstet Gynecol 1993; 168: 1759-1765
  6. Kirk E, Condous G, Bourne T. The nonsurgical management of ectopic pregnancy. Ultrasound Obstet Gynecol 2006; 27: 91-100
  7. Fernandez H, Lelaidier C, Thouvenez V,Frydman R. The use of a pretherapeutic, predictive score to determine inclusion criteria for the non-surgical treatment of ectopic pregnancy. Hum Reprod 1991; 6: 995-998
  8. Canis M, Savary D, Pouly JL, Wattiez A, Mage G. Ectopic pregnancy: criteria to decide betweenmedical and conservative surgical treatment? J Gynecol Obstet Biol Reprod 2003; 32: S54-63
  9. Potter MB, Lepine LA, Jamieson DJ. Predictors of success with methotrexate treatment of tubal ectopic pregnancy at Grady Memorial Hospital. Am J Obstet Gynecol 2003; 188: 1192-1194
  10. Nazac A, Gervaise A, Bouyer J, de Tayrac R, Capella-Allouc S, Fernandez H. Predictors of success in methotrexate treatment of women with unruptured tubal pregnancies. Ultrasound Obstet Gynecol 2003; 21: 181-185
  11. Dilbaz S, Caliskan E, Dilbaz B, Degirmenci O, Haberal A. Predictors of methotrexate treatment failure in ectopic pregnancy. J Reprod Med 2006; 51: 87-93
  12. Guvendag Guven ES, Dilbaz S, Dilbaz B, Aykan Yildirim B, Akdag D, Haberal A. Comparison of single and multiple dose methotrexate therapy for unruptured tubal ectopic pregnancy: a prospective randomized study. Acta Obstet Gynecol Scand 2010; 89: 889-895
  13. Lermann J, Segl P, Jud SM, et al. Low-dose methotrexate treatment in ectopic pregnancy: a retrospective analysis of 164 ectopic pregnancies treated between 2000 and 2008. Arch Gynecol Obstet 2014; 289: 329-335
  14. Richardson A. Medical management of ectopic pregnancy: a 10-year case series. Hum Fertil 2012; 15: 116-120.